Financials
Financial year 2025
Nuclear Medicine Europe from Elsene, company number BE0443242686, closed financial year 2025 with a result of € 22,407 after tax. For that financial year Nuclear Medicine Europe recorded a gross margin of € 293,758 and equity of € 181,000. Compared with financial year 2024, the result moved from € 7,393 to € 22,407. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 1, 2026.
€ 181,000
▲ 3% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 22,407
▲ 203% vs 2024
Profit after tax over the fiscal year.
€ 232,745
▼ 4% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 0.
People and assets in 2025
€ 257,559
▲ 5% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 4,195
▲ 41% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 26,692
▲ 8% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 27,703
▲ 1% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 105,466 | € 172,232 | € 261,341 | € 293,758 | ▲ 12% |
| Profit after taxes | € -110,554 | € -97,298 | € 7,393 | € 22,407 | ▲ 203% |
| Equity | € 141,000 | € 171,000 | € 176,000 | € 181,000 | ▲ 3% |
| Total debts | € 311,720 | € 265,063 | € 232,569 | € 257,200 | ▲ 11% |
| Cash | € 260,124 | € 181,368 | € 242,784 | € 232,745 | ▼ 4% |
| Balance sheet total | € 452,720 | € 436,063 | € 408,569 | € 438,200 | ▲ 7% |
Key figures of Nuclear Medicine Europe, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Nuclear Medicine Europe?
What happened at Nuclear Medicine Europe in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Konrade von BREMEN stepped down as director. NBB
- Matthew MORRISON stepped down as director. NBB
- ERICH KOLLEGGER stepped down as director. NBB
- ETIENNE BOQUIEN stepped down as director. NBB
- MARTINUS BLAUWHOFF stepped down as director. NBB
- CDP PETIT & CO -B00938 SRL stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 22,407 (▲ 203% vs 2024). Source: NBB ↗
- Konrade von BREMEN became a director. NBB
In short
From € 110,554 loss in 2022 to € 22,407 profit in 2025.
Paid € 151 in corporate taxes since 2022.
Best year ever: 2025, with € 22,407 profit.
A new publication or filing at Nuclear Medicine Europe? We notify you, reason included.
Follow Nuclear Medicine EuropeDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Directors
According to the 2025 annual accounts
Konrade von BREMEN
Director
since 2025 · until 2028
Matthew MORRISON
Director
since 2025 · until 2028
ERICH KOLLEGGER
Vice-président du conseil d'administration
since 2025 · until 2028
ETIENNE BOQUIEN
Director
since 2025 · until 2028
Commissaire-reviseur · represented by BENJAMIN GORLIER - nr membre A02357
Also active at: JEAN CRAB ET SES FILS, LR Technologies Belgium, CHATEAU LE DOCTE
since 2024 · until 2027
MARTINUS BLAUWHOFF
Chairman of the board
since 2025 · until 2028
Establishments
Establishment units
Physical locations of this company
Louizalaan 65 box 11
1050 Elsene
Louizalaan 65 box 4
1050 Elsene
Active since 19 February 1991
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0443.242.686
- VAT number
- BE 0443.242.686
- Registered office
- Louizalaan 65 bus 11, 1050 Elsene
- Names & denominations
- Nuclear Medicine Europe
- Enterprise type
- Rechtspersoon
- Legal form
- Europees economisch samenwerkingsverband
- Legal situation
- Normale toestand
- Start date
- 19 February 1991
- Peppol
- Active · Active since 24 Nov 2025
- Activities · NACE
Beroepsorganisaties
Activiteiten van beroepsorganisaties
Overige zakelijke dienstverlening, neg
Overige zakelijke dienstverlening, n.e.g.